EUVIMEDEUVIMED entdecken
Crossref

Serum ribonucleotide reductase M2 is a potential biomarker for diagnosing and monitoring liver fibrosis in chronic hepatitis B patients

Yating Zhan, Qiqi Tao, Zhichao Lang, Lifan Lin, Xinmiao Li, Suhui Yu, Zhengping Yu, Guangyao Zhou, Kaifeng Wu, Zhenxu Zhou, Zhixian Yu, Jianjian Zheng iD

Journal of Medical Virology · 2023

DOI: 10.1002/jmv.29157 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Yating Zhan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical Uni…. Hauptthemen laut MEDLINE: Hepatitis B, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Wenzhou Municipal Science and Technology Bureau, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It is known that ribonucleotide reductase M2 (RRM2) could be induced by hepatitis B virus (HBV) via DNA damage response. However, whether RRM2 is a potential biomarker for diagnosing and monitoring liver fibrosis in chronic hepatitis B (CHB) patients is still unclear. In this study, CHB patients from GSE84044 (a transcriptome data from GEO data set) were downloaded and RRM2 was selected as a hub gene. Interestingly, a positive correlation was found between serum RRM2 and liver fibrosis stage. The similar results were found in CHB patients with normal alanine aminotransferase (ALT). Notably, RRM2 could effectively differentiate preliminary fibrosis from advanced fibrosis in CHB patients with/without normal ALT. In addition, RRM2 had a better performance in diagnosing liver fibrosis than two commonly used noninvasive methods (aspartate aminotransferase‐to‐platelet ratio index and fibrosis index based on the four factors), two classic fibrotic biomarkers (hyaluronic acid and type IV collagen) as well as Mac‐2 binding protein glycosylation isomer, a known serum fibrosis marker. Moreover, CHB patients with high RRM2, who were associated with advanced fibrosis, had higher expressions of immune checkpoints. Overall, serum RRM2 may be a promising biomarker for diagnosing and monitoring liver fibrosis in CHB patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicHumansROC CurveLiver CirrhosisLiverHepatitis B virusFibrosisBiomarkersAlanine TransaminaseRibonucleoside Diphosphate Reductase

Stichwörter der Autor:innen

RRM2biomarkerchronic hepatitis Bdiagnosisliver fibrosis

Substanzen

BiomarkersAlanine Transaminaseribonucleotide reductase M2Ribonucleoside Diphosphate Reductase

Autor:innen und Institutionen

  • Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Department of Infectious Diseases, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
  • Department of Laboratory Medicine, The First People's Hospital of Zunyi, Zunyi, China.
  • Department of Hernia and Abdominal Wall Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

ORCID-Profile: Jianjian Zheng

Förderung

  • Wenzhou Municipal Science and Technology Bureau
  • National Natural Science Foundation of China

Zitieren

APA

Zhan, Y., Tao, Q., Lang, Z., Lin, L., Li, X., Yu, S., Yu, Z., Zhou, G., Wu, K., Zhou, Z., Yu, Z., & Zheng, J. (2023). Serum ribonucleotide reductase M2 is a potential biomarker for diagnosing and monitoring liver fibrosis in chronic hepatitis B patients. Journal of Medical Virology. https://doi.org/10.1002/jmv.29157

Vancouver

Zhan Y, Tao Q, Lang Z, Lin L, Li X, Yu S, et al. Serum ribonucleotide reductase M2 is a potential biomarker for diagnosing and monitoring liver fibrosis in chronic hepatitis B patients. Journal of Medical Virology. 2023. doi:10.1002/jmv.29157

BibTeX
@article{Zhan2023,
  author = {Zhan, Yating and Tao, Qiqi and Lang, Zhichao and Lin, Lifan and Li, Xinmiao and Yu, Suhui and Yu, Zhengping and Zhou, Guangyao and Wu, Kaifeng and Zhou, Zhenxu and Yu, Zhixian and Zheng, Jianjian},
  title = {Serum ribonucleotide reductase M2 is a potential biomarker for diagnosing and monitoring liver fibrosis in chronic hepatitis B patients},
  journal = {Journal of Medical Virology},
  year = {2023},
  doi = {10.1002/jmv.29157}
}
Kostenlos starten →